Lister Troy, Chief Scientific Officer at Verve Therapeutics ($VERV), made one open market sale of $VERV shares in the last 365 days, totaling $9,084. His most recent sale was on April 2, 2025. These transactions rank 11,292nd among 11,678 insiders, well below the average sale amount of $8.6 million and 6.4 transactions. Troy reported no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | U | Common Stock | 6952 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.01% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | D | Stock Option (right to buy) | 225000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.25% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | D | Restricted Stock Units | 40000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.04% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | D | Restricted Stock Units | 12075 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.01% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | D | Restricted Stock Units | 6630 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.01% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | D | Stock Option (right to buy) | 32000 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.04% |
| July 25, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | D | Stock Option (right to buy) | 69500 | $0.00 | 0.0000 | 89,143,237 | 100.00% | 0.08% |
| April 1, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | M | Common Stock | 7340 | $0.00 | 9,141.0000 | 88,795,768 | 407.55% | 0.01% |
| April 2, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | S | Common Stock | 2189 | $4.15 | 6,952.0000 | 88,795,768 | 23.95% | 0.00% |
| April 1, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | M | Restricted Stock Units | 3315 | $0.00 | 6,630.0000 | 88,795,768 | 33.33% | 0.00% |
| April 1, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | M | Restricted Stock Units | 4025 | $0.00 | 12,075.0000 | 88,795,768 | 25.00% | 0.00% |
| Jan. 8, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | A | Stock Option (right to buy) | 225000 | $0.00 | 225,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 8, 2025 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | A | Restricted Stock Units | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| June 21, 2024 | Verve Therapeutics, Inc. | $VERV | Lister Troy | Chief Scientific Officer | A | Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 0 | 9999.99% | 0.00% |